

DT14 Re US PCT/PTO 12 JAN 2005

PTO-1390 (Rev. 12-2004)

Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER CL2178USPCT
		U.S. APPLICATION No. (If known, see 37 CFR 1.5) 10/521369
INTERNATIONAL APPLICATION NO. PCT/US03/25883	INTERNATIONAL FILING DATE 14 August 2003 (14.08.03)	PRIORITY DATE CLAIMED 14 August 2002 (14.08.02)
TITLE OF INVENTION PROCESS FOR COATING A PHARMACEUTICAL PARTICLE		
APPLICANT(S) FOR DO/EO/US DALZIEL, Sean Mark Et. Al.		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input checked="" type="checkbox"/> The US has been elected (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p style="margin-left: 20px;">a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> has been communicated by the International Bureau.</p> <p style="margin-left: 20px;">c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> is attached hereto.</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> have been communicated by the International Bureau.</p> <p style="margin-left: 20px;">c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p style="margin-left: 20px;">d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p>Items 11 to 20 below concern document(s) or information included:</p> <p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input type="checkbox"/> A preliminary amendment.</p> <p>14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input checked="" type="checkbox"/> A power of attorney and/or change of address letter.</p> <p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input checked="" type="checkbox"/> Other items or information: EXPRESS LABEL EU9160100653 US IPER Request to change inventor Address.</p>		

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

DT12 Rec'd PCT/PTO 12 JAN 2005

PTO-1390 (Rev. 12-2004)

Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER	
10/521369		PCT/US03/25883		CL2178USPCT	
21. The following fees are submitted:					
<input checked="" type="checkbox"/> a) Basic national fee.....				\$300.00	\$ 300.00
<input checked="" type="checkbox"/> b) Examination fee.....				\$200.00	\$ 200.00
<input checked="" type="checkbox"/> c) Search fee.....				\$500.00	\$ 500.00
TOTAL OF ABOVE CALCULATIONS =				\$1000.00	\$ 1,000.00
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra sheets	Number of each additional 50 or fraction thereof (round up to a whole number)		RATE	
- 100 =	/50 =			x \$250.00	\$
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)). <input type="checkbox"/>					\$ 0.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total claims	35 - 20 =	15	x \$50.00	\$ 750.00	
Independent claims	6 - 3 =	3	x \$200.00	\$ 600.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable) YES <input checked="" type="checkbox"/>			+ \$360.00	\$ 360.00	
TOTAL OF ABOVE CALCULATIONS =				\$ 2,710.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.					\$ 0.00
SUBTOTAL =				\$ 2,710.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)). <input type="checkbox"/>					\$ 0.00
TOTAL NATIONAL FEE =				\$ 2,710.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property <input type="checkbox"/>					\$ 0.00
TOTAL FEES ENCLOSED =				\$ 2,710.00	
					Amount to be refunded: \$
					Amount to be charged: \$
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed.					
b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>04-1928</u> in the amount of \$ <u>2,710.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed.					
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit t Account No. <u>04-1928</u> . A duplicate copy of this sheet is enclosed.					
d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.					
SEND ALL CORRESPONDENCE TO:					
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>BOWEN, Alanson G. E. I. DU PONT DE NEMOURS AND COMPANY Legal Patent Records Center 4417 Lancaster Pike Wilmington, Delaware 19805 United States of America</p> </div> <div style="width: 50%;"> <p><i>Barbara C. Sigel</i> 30,684 SIGNATURE BOWEN, ALANSON G. NAME 24,027 REGISTRATION NUMBER</p> </div> </div>					

THE INTERNATIONAL BUREAU OF WIPO
and
THE EUROPEAN PATENT OFFICE

In the Application of:

E. I. DU PONT DE NEMOURS AND COMPANY

Case No.: CL2178 PCT

International Application No.: PCT/US03/25883

International Filing Date: August 14, 2003

For: PROCESS FOR COATING A PHARMACEUTICAL PARTICLE

Wilmington, Delaware 19898
Date: 02 December 2004

THE INTERNATIONAL BUREAU OF WIPO
34 Chemin des Colombettes
1211 Geneva 20
SWITZERLAND
SENT VIA FACSIMILE
#9-011-41-22-740-1435

EUROPEAN PATENT OFFICE
Erhardstrasse 27
D-88331 Munchen
GERMANY
SENT VIA FACSIMILE
#9-011-49-89-2399-4465

REQUEST PURSUANT TO PCT RULE 92^{bis}.1(a)(i)
ADDITION OR CORRECTION OF APPLICANT'S NAME AND ADDRESS

Applicant is filing this paper to inform the RO that the above applicant wishes to correct the name and address of applicant:


AS IS: Sean Mark Dalziel
2201 Bridgepointe Parkway
Suite G116
San Mateo, CA 94404-0000
U.S.A.

SHOULD BE: Sean Mark Dalziel
201 Harrison Street
Apt. 921
San Francisco, CA 94105-0000

ALL THE OTHER INFORMATION REMAINS THE SAME. Please update all the necessary records to reflect this change and republish the application.

Respectfully submitted,
E. I. DU PONT DE NEMOURS AND COMPANY

By:


ROGER A. BOWMAN
Assistant Secretary - Patent Board

FAX HEADER 1: 3029924773 DUPONT PAT REC CTR
FAX HEADER 2:TRANSMITTED/STORED : DEC. 2. 2004 1:29PM
FILE MODE OPTION

ADDRESS

RESULT

PAGE

5297 MEMORY TX

0041227401435

OK

1/1

REASON FOR ERROR
E-1) HANG UP OR LINE FAIL
E-3) NO ANSWERE-2) BUSY
E-4) NO FACSIMILE CONNECTION**THE INTERNATIONAL BUREAU OF WIPO
and
THE EUROPEAN PATENT OFFICE****In the Application of:****E. I. DU PONT DE NEMOURS AND COMPANY****Case No.: CL2178 PCT****International Application No.: PCT/US03/25883****International Filing Date: August 14, 2003****For: PROCESS FOR COATING A PHARMACEUTICAL PARTICLE**Wilmington, Delaware 19898
Date: 02 December 2004THE INTERNATIONAL BUREAU OF WIPO
34 Chemin des Colombettes
1211 Geneva 20
SWITZERLAND
SENT VIA FACSIMILE
#9-011-41-22-740-1435EUROPEAN PATENT OFFICE
Erhardstrasse 27
D-88331 Munchen
GERMANY
SENT VIA FACSIMILE
#9-011-49-89-2399-4485**REQUEST PURSUANT TO PCT RULE 92^{bis}, 1(a)(i)**
ADDITION OR CORRECTION OF APPLICANT'S NAME AND ADDRESS

Applicant is filing this paper to inform the RO that the above applicant wishes to correct the name and address of applicant:

AS IS: Sean Mark Dalziel
2201 Bridgepointe Parkway
Suite G116
San Mateo, CA 94404-0000
U.S.A.SHOULD BE: Sean Mark Dalziel
201 Harrison Street
Apt. 921
San Francisco, CA 94105-0000

ALL THE OTHER INFORMATION REMAINS THE SAME. Please update all the necessary records to reflect this change and republish the application.

Respectfully submitted,
E. I. DU PONT DE NEMOURS AND COMPANYBy: Roger A. Bowman
ROGER A. BOWMAN
Assistant Secretary - Patent Board